{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,20]],"date-time":"2026-03-20T17:50:58Z","timestamp":1774029058832,"version":"3.50.1"},"reference-count":32,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"4","license":[{"start":{"date-parts":[[2015,9,1]],"date-time":"2015-09-01T00:00:00Z","timestamp":1441065600000},"content-version":"tdm","delay-in-days":1248,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"crossref","award":["RO1 DA 15999-01"],"award-info":[{"award-number":["RO1 DA 15999-01"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"crossref"}]},{"name":"National Centre in HIV Epidemiology and Clinical Research"},{"DOI":"10.13039\/501100001027","name":"Australian Government Department of Health and Ageing","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100001027","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Faculty of Medicine, University of New South Wales"},{"name":"Roche Pharmaceuticals"},{"name":"pegylated IFN-alfa-2a\/ribavirin"},{"name":"National Health and Medical Research Council Practitioner Research Fellowships"},{"name":"National Health and Medical Research Council Career Development Award"},{"name":"VicHealth Senior Research Fellowship"},{"name":"National Health and Medical Research Council Research Fellowships"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2012,4]]},"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title\/>\n            <jats:p>The purpose of the study was to evaluate reinfection and superinfection during treatment for recent hepatitis C virus (HCV). The Australian Trial in Acute Hepatitis C (ATAHC) was a prospective study of the natural history and treatment of recent HCV. Reinfection and superinfection were defined by detection of infection with an HCV strain distinct from the primary strain (using reverse-transcription polymerase chain reaction [RT-PCR] and subtype-specific nested RT-PCR assays) in the setting of spontaneous or treatment-induced viral suppression (one HCV RNA &lt;10 IU\/mL) or persistence (HCV RNA &gt;10 IU\/mL from enrollment to week 12). Among 163 patients, 111 were treated, 79% (88 of 111) had treatment-induced viral suppression, and 60% (67 of 111) achieved sustained virological response. Following treatment-induced viral suppression, recurrence was observed in 19% (17 of 88), including 12 with relapse and five with reinfection (4.7 cases per 100 person-years [PY], 95% confidence interval [CI]: 1.9, 11.2). Among 52 untreated patients, 58% (30 of 52) had spontaneous viral suppression and recurrence was observed in 10% (3 of 30), including two with reinfection. Following reinfection, alanine aminotransferase (ALT) levels &gt;1.5\u00d7 the upper limit of normal were observed in 71% (5 of 7). Among 37 with persistence, superinfection was observed in 16% (3 of 19) of those treated and 17% (3 of 18) of those untreated. In adjusted analysis, reinfection\/superinfection occurred more often in participants with poorer social functioning at enrollment and more often in those with ongoing injecting drug use (IDU). <jats:italic toggle=\"yes\">Conclusion<\/jats:italic>: Reinfection and superinfection can occur during treatment of recent HCV and are associated with poor social functioning and ongoing IDU. ALT levels may be a useful clinical marker of reexposure. (Hepatology 2012)<\/jats:p>\n          <\/jats:sec>","DOI":"10.1002\/hep.24754","type":"journal-article","created":{"date-parts":[[2011,10,26]],"date-time":"2011-10-26T16:13:29Z","timestamp":1319645609000},"page":"1058-1069","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":79,"title":["Hepatitis C virus reinfection and superinfection among treated and untreated participants with recent infection"],"prefix":"10.1097","volume":"55","author":[{"given":"Jason","family":"Grebely","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Son Truong","family":"Pham","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gail V.","family":"Matthews","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kathy","family":"Petoumenos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rowena A.","family":"Bull","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Barbara","family":"Yeung","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"William","family":"Rawlinson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John","family":"Kaldor","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrew","family":"Lloyd","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Margaret","family":"Hellard","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gregory J.","family":"Dore","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peter A.","family":"White","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"R1-9-20241201","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1016\/S1473-3099(05)70216-4","article-title":"Global epidemiology of hepatitis C virus infection.","volume":"5","author":"Shepard","year":"2005","journal-title":"Lancet Infect Dis"},{"key":"R2-9-20241201","doi-asserted-by":"crossref","first-page":"1350","DOI":"10.1136\/gut.2005.076646","article-title":"Treating viral hepatitis C: efficacy, side effects, and complications.","volume":"55","author":"Manns","year":"2006","journal-title":"Gut"},{"key":"R3-9-20241201","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1111\/j.1365-2893.2009.01080.x","article-title":"Low uptake of treatment for hepatitis C virus infection in a large communitybased study of inner city residents.","volume":"16","author":"Grebely","year":"2009","journal-title":"J Viral Hepat"},{"key":"R5-9-20241201","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1007\/s10900-007-9083-3","article-title":"Limited uptake of hepatitis C treatment among injection drug users.","volume":"33","author":"Mehta","year":"2008","journal-title":"J Community Health"},{"key":"R6-9-20241201","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1300\/J069v27n02_04","article-title":"Current approaches to HCV infection in current and former injection drug users.","volume":"27","author":"Grebely","year":"2008","journal-title":"J Addict Dis"},{"key":"R7-9-20241201","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1086\/600304","article-title":"Hepatitis C treatment for injection drug users: a review of the available evidence.","volume":"49","author":"Hellard","year":"2009","journal-title":"Clin Infect Dis"},{"key":"R8-9-20241201","doi-asserted-by":"crossref","first-page":"1540","DOI":"10.1086\/425361","article-title":"Infrequent reinfection after successful treatment for hepatitis C virus infection in injection drug users.","volume":"39","author":"Backmund","year":"2004","journal-title":"Clin Infect Dis"},{"issue":"Suppl 5","key":"R9-9-20241201","doi-asserted-by":"crossref","first-page":"S336","DOI":"10.1086\/427449","article-title":"Followup studies of treatment for hepatitis C virus infection among injection drug users.","volume":"40","author":"Dalgard","year":"2005","journal-title":"Clin Infect Dis"},{"key":"R10-9-20241201","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1016\/j.drugalcdep.2007.09.011","article-title":"A prospective study to examine persistent HCV reinfection in injection drug users who have previously cleared the virus.","volume":"93","author":"Currie","year":"2008","journal-title":"Drug Alcohol Depend"},{"key":"R11-9-20241201","doi-asserted-by":"crossref","first-page":"1281","DOI":"10.1111\/j.1440-1746.2010.06238.x","article-title":"Reinfection with hepatitis C virus following sustained virological response in injection drug users.","volume":"25","author":"Grebely","year":"2010","journal-title":"J Gastroenterol Hepatol"},{"key":"R12-9-20241201","doi-asserted-by":"crossref","first-page":"1276","DOI":"10.1111\/j.1440-1746.2010.06295.x","article-title":"High prevalence of late relapse and reinfection in prisoners treated for chronic hepatitis C.","volume":"25","author":"Bate","year":"2010","journal-title":"J Gastroenterol Hepatol"},{"key":"R13-9-20241201","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1086\/510858","article-title":"Hepatitis C virus coinfection and superinfection.","volume":"195","author":"Blackard","year":"2007","journal-title":"J Infect Dis"},{"key":"R14-9-20241201","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1086\/431682","article-title":"HIV superinfection.","volume":"192","author":"Smith","year":"2005","journal-title":"J Infect Dis"},{"key":"R16-9-20241201","doi-asserted-by":"crossref","first-page":"1564","DOI":"10.1002\/hep.23885","article-title":"Frequent multiple hepatitis C virus infections among injection drug users in a prison setting.","volume":"52","author":"Pham","year":"2010","journal-title":"HEPATOLOGY"},{"key":"R17-9-20241201","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1111\/j.1360-0443.1992.tb02719.x","article-title":"Development and validation of a multidimensional instrument for assessing outcome of treatment among opiate users: the Opiate Treatment Index.","volume":"87","author":"Darke","year":"1992","journal-title":"Br J Addict"},{"key":"R18-9-20241201","doi-asserted-by":"crossref","first-page":"8183","DOI":"10.1128\/JVI.00142-08","article-title":"Previously infected chimpanzees are not consistently protected against reinfection or persistent infection after reexposure to the identical hepatitis C virus strain.","volume":"82","author":"Bukh","year":"2008","journal-title":"J Virol"},{"key":"R19-9-20241201","doi-asserted-by":"crossref","first-page":"1725","DOI":"10.1128\/JVI.72.3.1725-1730.1998","article-title":"Immunity in chimpanzees chronically infected with hepatitis C virus: role of minor quasispecies in reinfection.","volume":"72","author":"Wyatt","year":"1998","journal-title":"J Virol"},{"key":"R20-9-20241201","doi-asserted-by":"crossref","first-page":"1645","DOI":"10.1084\/jem.20030239","article-title":"Memory CD8 T cells are required for protection from persistent hepatitis C virus infection.","volume":"197","author":"Shoukry","year":"2003","journal-title":"J Exp Med"},{"key":"R21-9-20241201","doi-asserted-by":"crossref","first-page":"6586","DOI":"10.1128\/JVI.76.13.6586-6595.2002","article-title":"Previously infected and recovered chimpanzees exhibit rapid responses that control hepatitis C virus replication upon rechallenge.","volume":"76","author":"Major","year":"2002","journal-title":"J Virol"},{"key":"R22-9-20241201","doi-asserted-by":"crossref","first-page":"1479","DOI":"10.1053\/jhep.2001.24371","article-title":"Protective immune response to hepatitis C virus in chimpanzees rechallenged following clearance of primary infection.","volume":"33","author":"Bassett","year":"2001","journal-title":"HEPATOLOGY"},{"key":"R23-9-20241201","doi-asserted-by":"crossref","first-page":"900","DOI":"10.1136\/gut.52.6.900","article-title":"Second infection with a different hepatitis C virus genotype in a intravenous drug user during interferon therapy.","volume":"52","author":"Asselah","year":"2003","journal-title":"Gut"},{"key":"R24-9-20241201","doi-asserted-by":"crossref","first-page":"1131","DOI":"10.1002\/hep.1840200505","article-title":"Superinfection of chimpanzees carrying hepatitis C virus of genotype II1b with that of genotype III2a or I1a.","volume":"20","author":"Okamoto","year":"1994","journal-title":"HEPATOLOGY"},{"key":"R25-9-20241201","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1002\/(SICI)1096-9071(199612)50:4<303::AID-JMV4>3.0.CO;2-C","article-title":"Superinfection by homotypic virus in hepatitis C virus carriers: studies on patients with posttransfusion hepatitis.","volume":"50","author":"Kao","year":"1996","journal-title":"J Med Virol"},{"key":"R26-9-20241201","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1097\/00007890-199510150-00004","article-title":"Hepatitis C superinfection in hepatitis C virus (HCV)infected patients transplanted with an HCVinfected kidney.","volume":"60","author":"Widell","year":"1995","journal-title":"Transplantation"},{"key":"R27-9-20241201","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1016\/S0016-5085(03)00668-1","article-title":"Acute hepatitis C: high rate of both spontaneous and treatmentinduced viral clearance.","volume":"125","author":"Gerlach","year":"2003","journal-title":"Gastroenterology"},{"key":"R28-9-20241201","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1053\/j.gastro.2009.09.017","article-title":"Spontaneous control of primary hepatitis C virus infection and immunity against persistent reinfection.","volume":"138","author":"Osburn","year":"2010","journal-title":"Gastroenterology"},{"key":"R29-9-20241201","doi-asserted-by":"crossref","first-page":"1478","DOI":"10.1016\/S0140-6736(02)08435-0","article-title":"Protection against persistence of hepatitis C.","volume":"359","author":"Mehta","year":"2002","journal-title":"Lancet"},{"key":"R30-9-20241201","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.1002\/hep.21376","article-title":"Hepatitis C virus reinfection in injection drug users.","volume":"44","author":"Grebely","year":"2006","journal-title":"HEPATOLOGY"},{"key":"R31-9-20241201","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1111\/j.1365-2893.2006.00812.x","article-title":"High incidence of hepatitis C virus reinfection within a cohort of injecting drug users.","volume":"14","author":"Micallef","year":"2007","journal-title":"J Viral Hepat"},{"key":"R32-9-20241201","doi-asserted-by":"crossref","first-page":"1746","DOI":"10.1002\/hep.22534","article-title":"High incidence of hepatitis C virus reinfection in a cohort of injecting drug users.","volume":"48","author":"Aitken","year":"2008","journal-title":"HEPATOLOGY"},{"key":"R33-9-20241201","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1016\/j.jhep.2009.05.027","article-title":"Frequent HCV reinfection and superinfection in a cohort of injecting drug users in Amsterdam.","volume":"51","author":"van de Laar","year":"2009","journal-title":"J Hepatol"},{"key":"R34-9-20241201","doi-asserted-by":"crossref","first-page":"1216","DOI":"10.1086\/605947","article-title":"Acute hepatitis C virus infection in young adult drug users: a prospective study of incident infection, resolution and reinfection.","volume":"200","author":"Page","year":"2009","journal-title":"J Infect Dis"}],"container-title":["Hepatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fhep.24754","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.lww.com\/01515467-201204000-00009","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T13:36:43Z","timestamp":1733060203000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/01515467-201204000-00009"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,4]]},"references-count":32,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2012]]}},"URL":"https:\/\/doi.org\/10.1002\/hep.24754","relation":{},"ISSN":["0270-9139"],"issn-type":[{"value":"0270-9139","type":"print"}],"subject":[],"published":{"date-parts":[[2012,4]]}}}